Creating new antidotes for blood thinners using zebrafish
Development of novel anticoagulant antidotes using zebrafish
['FUNDING_R21'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10848935
This study is looking for new ways to quickly stop severe bleeding caused by superwarfarins, a type of blood thinner, using zebrafish to help find better treatments for people who might have overdosed on these medications.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10848935 on ClinicalTrials.gov |
What this research studies
This research focuses on developing novel antidotes for anticoagulants, particularly superwarfarins, which can cause severe bleeding when overdosed. By utilizing zebrafish as a biological model, the team aims to explore innovative methods to counteract the effects of these anticoagulants more effectively and rapidly than current treatments. The study will investigate the mechanisms of blood coagulation and how new compounds can be used to reverse the effects of these drugs. This approach could lead to safer and more efficient treatments for patients experiencing anticoagulant-related emergencies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of anticoagulant overdose, including those on long-term anticoagulant therapy or those exposed to superwarfarins.
Not a fit: Patients who do not use anticoagulants or are not at risk of bleeding complications from anticoagulant therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide faster and more effective treatments for patients suffering from severe bleeding due to anticoagulant overdoses.
How similar studies have performed: Previous research has shown promise in developing antidotes for anticoagulants, but this specific approach using zebrafish is relatively novel.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHAVIT, JORDAN A — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: SHAVIT, JORDAN A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.